253 related articles for article (PubMed ID: 34733788)
21. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
He Y; Ju Y; Hu Y; Wang B; Che S; Jian Y; Zhuo W; Fu X; Cheng Y; Zheng S; Huang N; Qian Z; Liu J; Zhou P; Gao X
J Control Release; 2023 Feb; 354():155-166. PubMed ID: 36538950
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
23. Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable'
Saraswat A; Patki M; Fu Y; Barot S; Dukhande VV; Patel K
Nanomedicine (Lond); 2020 Aug; 15(18):1761-1777. PubMed ID: 32698663
[No Abstract] [Full Text] [Related]
24. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
26. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
28. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
29. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
30. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.
Saraswat A; Vemana HP; Dukhande VV; Patel K
Heliyon; 2022 Jan; 8(1):e08702. PubMed ID: 35036599
[TBL] [Abstract][Full Text] [Related]
31. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
[TBL] [Abstract][Full Text] [Related]
32. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of quinazolin-4(3
Chang X; Sun D; Shi D; Wang G; Chen Y; Zhang K; Tan H; Liu J; Liu B; Ouyang L
Acta Pharm Sin B; 2021 Jan; 11(1):156-180. PubMed ID: 33532187
[TBL] [Abstract][Full Text] [Related]
35. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
36. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.
Bauer K; Berghoff AS; Preusser M; Heller G; Zielinski CC; Valent P; Grunt TW
Am J Cancer Res; 2021; 11(2):530-545. PubMed ID: 33575085
[TBL] [Abstract][Full Text] [Related]
37. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
38. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
39. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
40. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
Rathod D; Fu Y; Patel K
Eur J Pharm Sci; 2019 Oct; 138():105039. PubMed ID: 31394259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
